Lilly Alzheimer's drug fails to slow memory loss in big study

(Reuters) - Eli Lilly and Co experimental drug solanezumab failed to slow loss of cognitive ability in patients with mild Alzheimer's disease in a large trial, a major setback for the U.S. drugmaker and millions of people with the memory-robbing disease.